Literature DB >> 3526889

Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy.

M Suarez, P W Ho, E S Johnson, G Perez.   

Abstract

Captopril, an angiotensin converting enzyme inhibitor used in the treatment of hypertension, has been associated with hematologic as well as dermatologic side effects. Two patients with captopril-induced angioneurotic edema, one of whom had fatal granulocytopenia and overwhelming polymicrobial sepsis, are presented.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3526889     DOI: 10.1016/0002-9343(86)90274-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

1.  Severe angioedema and respiratory distress associated with lisinopril use.

Authors:  G W Soo Hoo; H T Dao; W B Klaustermeyer
Journal:  West J Med       Date:  1993-04

2.  Enalaprilat, but not cilazaprilat, increases inflammatory skin reactions in guinea-pigs.

Authors:  R G Andersson; B E Karlberg; B R Lindgren; K Persson; U Rosenqvist
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

Review 4.  Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.

Authors:  R C Parish; L J Miller
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

Review 5.  Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review.

Authors:  B R Lindgren; R G Andersson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct

Review 6.  Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?

Authors:  Laurence G Howes; Diane Tran
Journal:  Drug Saf       Date:  2002       Impact factor: 5.228

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.